Added to YB: 2026-01-27
Pitch date: 2026-01-24
PHARM.AS [neutral]
Pharming Group N.V.
-15.62%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Market Cap
EUR 1.3B
Pitch Price
EUR 1.67
Price Target
N/A
Dividend
N/A
EV/EBITDA
25.98
P/E
9.0K
EV/Sales
3.62
Sector
Biotechnology
Category
growth
Four Biotechs I’m Watching After the JPM Healthcare Conference - Pharming Group N.V.
PHARM.AS (watchlist): Pharming Group awaits Jan 31, 2026 FDA decision on Leniolisib (Joenja) pediatric expansion for rare APDS. Label expansion to ages 4-11 would broaden addressable population for already-approved PI3Kδ inhibitor. Lower binary risk vs new drug approval but meaningful commercial upside potential.
Read full article (2 min)